Research and Markets (http://www.researchandmarkets.com/research/k42ktc/targacepts) has announced the addition of the "Targacept's TC-5214: Neuronal nicotine receptors - a target for depression therapy" report to their offering.
Targacept is developing TC-5214 for adjunctive use in major depressive disorder. It is a selective neuronal nicotinic receptor antagonist and the S-isomer of mecamylamine (Inversine), a drug previously marketed for use in resistant hypertension. This report reviews phase II data and the probability that phase III trials will show efficacy. Although Chantix (indicated for smoking cessation) and Wellbutrin/Zyban (indicated for depression/smoking cessation) also impact this receptor family, TC-5214's pharmacology is unique enough that those experiences may not fully predict FDA's response to this novel agent. If successful, the adjunctive therapy niche seems promising. To date, only Abilify and Seroquel, two atypical antipsychotics compete in that space. However, many novel agents are in the pipeline and thus competition will be stiff.
- Clinical Picture
- Disease Mechanisms
- Current Treatment Paradigms
- Where Will Neuronal Nicotinic Receptors (Nnrs) Fit In This Picture?
1. Preclinical Profile
2. Clinical Data
- Tc-5214 --Phase Iib
CLINICAL AND REGULATORY DISCUSSION
1. Guidance Documents And Precedents Provide Insight Into FDA Thinking
2. What Nnr-Specific Issues Are Likely To Surface?
- Chantix As Precedent
- Bupropion (Wellbutrin And Zyban) As Precedent
- Other Potential Uses Suggest Opportunity And Risk
2. The Adjunctive Therapy Niche
For more information visithttp://www.researchandmarkets.com/research/k42ktc/targacepts.Business Wire
Last updated on: 07/01/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.